Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pahl

Showing results (151-160 of 174) with videos related to

Pageof 18
Sort By:
Molecular Pharmacology|September 20, 2007
Repression of T-cell function by thionamides is mediated by inhibition of the activator protein-1/nuclear factor of activated T-cells pathway and is associated with a common structureMatjaz Humar, Hannah Dohrmann, Philipp Stein, et al.
Blood|March 10, 2018
Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasmsJan C Peeken, Jonas S Jutzi, Julius Wehrle, et al.
Annals of Hematology|October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
European Journal of Haematology|July 7, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical RoutineSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Leukemia|August 4, 2012
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitorsF U Wöhrle, S Halbach, K Aumann, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
Leukemia Research|September 24, 2020
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathyNora Rebeka Javorniczky, Julius Wehrle, Gabriele Ihorst, et al.
Experimental Hematology|March 20, 2026
From Image to Insight: Optimized Multiplex Staining Panel for FFPE Mouse Bone Marrow Enables Spatial Profiling of the Hematopoietic NicheFranziska Zell, Katharina Gellrich, Albert Gründer, et al.
British Journal of Haematology|July 6, 2018
Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatmentJuliane M Stosch, Anezka Heumüller, Christoph Niemöller, et al.
The Journal of Experimental Medicine|April 17, 2013
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2Jonas S Jutzi, Ruzhica Bogeska, Gorica Nikoloski, et al.
Pageof 18

Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
Molecular Pharmacology|September 20, 2007
Repression of T-cell function by thionamides is mediated by inhibition of the activator protein-1/nuclear factor of activated T-cells pathway and is associated with a common structureMatjaz Humar, Hannah Dohrmann, Philipp Stein, et al.
Blood|March 10, 2018
Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasmsJan C Peeken, Jonas S Jutzi, Julius Wehrle, et al.
Annals of Hematology|October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
European Journal of Haematology|July 7, 2025
Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical RoutineSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Leukemia|August 4, 2012
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitorsF U Wöhrle, S Halbach, K Aumann, et al.
Leukemia|February 9, 2016
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or bothS Koschmieder, T I Mughal, H C Hasselbalch, et al.
Leukemia Research|September 24, 2020
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathyNora Rebeka Javorniczky, Julius Wehrle, Gabriele Ihorst, et al.
Experimental Hematology|March 20, 2026
From Image to Insight: Optimized Multiplex Staining Panel for FFPE Mouse Bone Marrow Enables Spatial Profiling of the Hematopoietic NicheFranziska Zell, Katharina Gellrich, Albert Gründer, et al.
British Journal of Haematology|July 6, 2018
Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatmentJuliane M Stosch, Anezka Heumüller, Christoph Niemöller, et al.
The Journal of Experimental Medicine|April 17, 2013
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2Jonas S Jutzi, Ruzhica Bogeska, Gorica Nikoloski, et al.
Pageof 18